Variations in PSA doubling time in patients with prostate cancer on "watchful waiting": Value of short-term PSADT determinations

Urology

Volumn 64, Issue 2, 2004, Pages 323-328

  Ross, Phillip L ^a   Mahmud, Salaheddin ^a   Stephenson, Andrew J ^a   Souhami, Luis ^a   Tanguay, Simon ^a   Aprikian, Armen G ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN DETERMINATION; STATISTICAL SIGNIFICANCE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CASE MANAGEMENT; COHORT STUDIES; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 4143109281     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.03.020     Document Type: Article

References (20)

1. Berger A.P., Spranger R., Kofler K., et al. Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens. Prostate. 57:2003;93-98
2. Carter H.B., Sauvageot J., Walsh P.C., et al. Prospective evaluation of men with stage T1c adenocarcinoma of the prostate. J Urol. 157:1997;2206-2209
3. Kattan M.W., Eastham J.A., Wheeler T.M., et al. Counseling men with prostate cancer a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol. 170:2003;1792-1797
4. Kakehi Y., Kamoto T., Shiraishi T., et al. Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men. Eur Urol. 41:2002;47-53
5. Do V., Choo R., De Boer G., et al. The role of serial free/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer. BJU Int. 89:2002;703-709
6. Choo R., Klotz L., Danjoux C., et al. Feasibility study watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol. 167:2002;1664-1669
7. Vollmer R.T., Egawa S., Kuwao S., et al. The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma a study of 94 Japanese men. Cancer. 94:2002;1692-1698
8. McLaren D.B., McKenzie M., Duncan G., et al. Watchful waiting or watchful progression prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer. 82:1998;342-348
9. Choo R., DeBoer G., Klotz L., et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys. 50:2001;615-620
10. Stephenson A.J., Aprikian A.G., Souhami L., et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology. 59:2002;652-656
11. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281:1999;1591-1597
12. Patel A., Dorey F., Franklin J., et al. Recurrence patterns after radical retropubic prostatectomy clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 158:1997;1441-1445
13. Roberts S.G., Blute M.L., Bergstralh E.J., et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 76:2001;576-581
14. D'Amico A.V., Cote K., Loffredo M., et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol. 20:2002;4567-4573
15. Soergel T.M., Koch M.O., Foster R.S., et al. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. J Urol. 166:2001;2198-2201
16. Schmid H.P., McNeal J.E., Stamey T.A. Observations on the doubling time of prostate cancer the use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer. 71:1993;2031-2040
17. Feinstein AR: Evaluating concordances, in Principles of Medical Statistics. New York, Chapman and Hall/CRC, 2002, pp 413-419
18. Landis J.R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics. 33:1977;159-174
19. Stamey T.A., Kabalin J.N., McNeal J.E., et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol. 141:1989;1076-1083
20. Eastham J.A., Riedel E., Scardino P.T., et al. the Polyp Prevention Trial Study Group. Variation of serum prostate-specific antigen levels an evaluation of year-to-year fluctuations. JAMA. 289:2003;2695-2700